STTK Shattuck Labs
- 7.915
- +0.075+0.96%
- 8.200
- +0.285+3.60%
Shattuck Labs News
HC Wainwright & Co. : The Shattuck Labs (STTK.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. : The Shattuck Labs (STTK.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
TD Cowen Remains a Buy on Shattuck Labs (STTK)
Promising Clinical Trial Results Support a Buy Rating for Shattuck Labs
Shattuck Labs to Present Additional Data From the Phase 1B Dose Expansion Clinical Trial of SL-172154 With Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 Mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK) today announced the presentation of additional data from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in frontline HR-MDS and TP53m AML patients.
Buy Rating Affirmed: Shattuck Labs' Promising Clinical Developments in HR-MDS and AML Treatment
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)
Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
Buy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154
HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $28 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price target.
Shattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical Milestones
Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Shattuck Labs Q1 2024 GAAP EPS $(0.37) Beats $(0.46) Estimate, Sales $1.115M Beat $228.500K Estimate
Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 24.49 percent increase over losses of $(0.49
Shattuck Labs 1Q Loss/Shr 37c >STTK
Shattuck Labs 1Q Loss/Shr 37c >STTK
Press Release: Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Le
28% Of This Shattuck Labs Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Shattuck Labs, Inc.'s (NASDAQ:STTK ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. Althou
Owning 36% Shares,institutional Owners Seem Interested in Shattuck Labs, Inc. (NASDAQ:STTK),
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
Analysis
Price Target
No Data
